MORRISTOWN, N.J., Sept. 14, 2016 /PRNewswire/ -- PLT Health Solutions, Inc. has introduced an important new weight management ingredient that has been clinically shown to deliver statistically significant weight loss starting at 2 weeks, sustained weight loss and a slimming effect on stomach, waist and hips. Called SLIMVANCE Core Slimming Complex, the ingredient is a patented, synergistic formulation of three well-known spices. SLIMVANCE's patented approach works at multiple levels by inhibiting the accumulation of fat into fat cells (lipogenesis) and enhancing the body's ability to break down fat cells (lipolysis). A 2016 16-week double-blind, placebo controlled study of SLIMVANCE, conducted with a healthy population of overweight men and women, sets new standards for communicating efficacy to consumers and regulatory agencies in the weight management category – because of its size, its length, its use of non-obese subjects and its design and execution. Consistent body weight reductions were observed throughout the 16-week trial – starting with statistically significant weight loss at 2 weeks, with a total weight loss of nearly 12 lbs. by the end of the study. These overweight subjects taking SLIMVANCE lost 2 inches in waist circumference in the study.
According to Seth Flowerman, Executive Vice President of PLT Health Solutions, the search for new weight solutions involves cutting-edge discovery but also quality clinical science to create compelling solutions that consumers can trust. "The synergistic combination of three spice extracts that constitute SLIMVANCE were selected from hundreds of different herbs examined using sophisticated screening techniques. They were studied to assess their ability to work synergistically to inhibit fat accumulation and promote the breakdown of fat in mature fat cells. The final combination showed the best potential, which were then studied in pre-clinical and clinical trials," he said. "SLIMVANCE has been the subject of two quality human clinical trials. The most recent trial was designed to further demonstrate the efficacy of SLIMVANCE and strengthen our ability to communicate its effectiveness in aiding in weight management. We feel that this approach is the best way to ultimately build trust with consumers.
Large Gold-Standard Clinical Study on Overweight Men & Women SLIMVANCE has been studied in two human clinical trials to date. The design and results of the most recent clinical research on SLIMVANCE Core Slimming Complex, which will be published later this year, offer a range of significant opportunities for leading consumer weight management products. Analyses indicate that statistically significant (p<0.0001) reductions in key measures were observed beginning within 2 weeks.
According to Dr. Barbara Davis, Vice President of Medical & Scientific Affairs for PLT Health Solutions, this study sets important standards for communicating efficacy to the consumer. "In the recent study, participants included both men and women. The subjects were of a broad age range, and were a healthy population of overweight – not obese – individuals, adding confidence to performance in the general population. The length of this trial demonstrates steady, consistent weight loss – starting early, and supporting long-term weight loss success. Finally, the trial demonstrates significantly significant slimming – with a reduction in waist circumference, and maintenance of lean body mass," she said. "AT PLT we designed this trial with the latest guidance from regulatory agencies in mind, but also to help give our customers confidence in the performance of SLIMVANCE across a broad section of the population., We look forward to working with our customers to help communicate the significance of these trial results in the development of new weight management products that consumers can understand and trust," she added. For more information, visit www.plthealth.com/SLIMVANCE.
Media Contact: Mark Falconer Sciencewerks Voice: 407-412-9705 E-mail
Company Contact: Steve Fink PLT Health Solutions, Inc. Voice: 973-984-0900 x214 E-mail